DGAP-News

Biotest AG: Biotest supports a large international retrospective study to record data on clinical use of Cytotect(R) after heart and lung transplantation - Seite 2

infection," Associate Professor Dr. Florian Wagner emphasises. "Because of
the immunological mode of action of the CMV hyperimmunoglobulin, which not
only neutralises viruses but also has a positive influence on the
transplant patient's immune system, the number of CMV infections and their
complications following transplantation can possibly be greatly reduced.
Furthermore, it is possible that Cytotect(R) will have a positive effect on
the health of the transplant patient and increase overall survival."

Based on the results of this study, Biotest intends to conduct further
prospective studies. Positive results could lead to an adaptation of the
international treatment guidelines for transplant physicians with inclusion
of Cytotect(R) into the standard therapy for heart and lung transplant
patients.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and
markets immunoglobulins, coagulation factors and albumins based on human
blood plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of cancer of plasma cells and systemic lupus erythematosus
which are produced by recombinant technologies. Biotest has more than 2,500
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: [phone]
email: [e-mail]

PR contact
Dirk Neumüller
phone: [phone]
email: [e-mail]

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.de

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover,
Munich, Stuttgart

Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.

[1] Germer M, Herbener P, Schüttrumpf J. Functional Properties of Human
Cytomegalovirus Hyperimmunoglobulin and Standard Immunoglobulin
Preparations. Annals of Transplantation. 2016; 21.


---------------------------------------------------------------------------

23.11.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: [e-mail]
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange


End of News DGAP News Service
---------------------------------------------------------------------------

523257 23.11.2016